Infinity Reports Preclinical Data for IPI-145 and Announces Initial Indications for Phase 2 ...
13:52 EDT 30 Jun 2012 | LaMerie
– Preclinical Data Demonstrate Potent PI3K-Delta and -Gamma Inhibition and Activity in Multiple Models of Inflammatory Disease –
Original Article: Infinity Reports Preclinical Data for IPI-145 and Announces Initial Indications for Phase 2 ...
More From BioPortfolio on "Infinity Reports Preclinical Data for IPI-145 and Announces Initial Indications for Phase 2 ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
